stockrow
Friday 6 November 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
154.46
11.27
+7.87%
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) EPS (diluted)
Belite Bio, Inc. Sponsored ADR's EPS (diluted) for fiscal 2025 was −$2.31, compared with −$1.18 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.73. Over the past ten years it has ranged from −$2.31 (fiscal 2025) to −$0.65 (fiscal 2022) — the current reading is the lowest in ten years. Belite Bio, Inc. Sponsored ADR ranks 359th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.31 | — |
| FY2024 | −$1.18 | — |
| FY2023 | −$1.19 | — |
| FY2022 | −$0.65 | — |
| FY2021 | −$1.01 | — |
| FY2020 | −$0.65 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.70 | — |
| Mar 2026 | −$0.68 | — |
| Dec 2025 | −$0.70 | — |
| Sep 2025 | −$0.65 | — |
| 12 more quarters | Free account |
Against its own ten years
Low −$2.31
High −$0.65
Ten-year median
−$1.10
Current reading's percentile
17
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $2.24 |
| PTCT PTC Therapeutics, Inc. compare | −$1.40 |
| ORKA Oruka Therapeutics, Inc. compare | −$2.12 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item